The National Dengue Task Force does not recommend the return of the Dengvaxia, as it cited evidence to show that the vaccine is not even preventing dengue infection.
“In Calabarzon, there are patients who were vaccinated but still developed dengue. So what’s the use of bringing back Dengvaxia?” said the task force chairman and Department of Health (DOH) regional director for CALABARZON, Eduardo Janairo.
Health Secretary Francisco Duque III created this task force last month to accord the monitoring and granting of medical assistance to all the vaccinated children in CALABARZON, Central Luzon, National Capital Region, and Western Visayas for five to 10 years.
DOH Epidemiology Bureau director Ferchito Avelino also said that he would not suggest the revival of Dengvaxia in mass immunization, although noted that individuals could avail if they want the vaccine for themselves.
Janairo emphasized the 833, 000 students from public elementary schools, who were given the vaccine.
The CALABARZON region has a total registered 172, 000 vaccinees, wherein 26 already developed dengue in the past week alone, and 98 have already acquired the virus since January 2019.
For him, the 26 cases already disprove the claim of Dengvaxia, where seven out of the number even received the complete cycle of three doses of the vaccine.
“There is no way to identify the persons who have had infections in the past and that’s the reason we cannot give that vaccine again,” Janairo stated this, adding the information that the parents of vaccinees strongly object to the return of the Dengvaxia in the Philippine market.
In February, the Food and Drug Administration (FDA) had permanently cancelled the certificate of product registration (CPR) of Dengvaxia after the manufacturer Sanofi Pasteur failed to submit post-marketing surveillance on the products.